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A B S T R A C T
Comprehensive pathogenesis studies on Peste des Petits Ruminants virus (PPRV) have been delayed so far by the
absence of a small animal model reproducing the disease or an in vitro biological system revealing virulence
differences. In this study, a mouse 10T1/2 cell line has been identified as presenting different susceptibility to
virulent and attenuated PPRV strains. As evidenced by immunofluorescence test and RT-PCR, both virulent and
attenuated PPR viruses penetrated and initiated the replication cycle in 10T1/2 cells, independently of the
presence of the SLAM goat receptor. However, only virulent strains successfully completed their replication cycle
while the vaccine strains did not. Since 10T1/2 cells are interferon-producing cells, the role of the type I in-
terferon (type I IFN) response on this differentiated replication between virulent and attenuated strains was
verified by stimulation or repression. Modulation of the type I IFN response did not improve the replication of
the vaccine strains, indicating that other cell factor(s) not yet established may hinder the replication of atte-
nuated PPRV in 10T1/2. This 10T1/2 cell line can be proposed as a new in vitro tool for PPRV-host interaction
and virulence studies.
1. Introduction
Peste des Petits Ruminants (PPR) is an acute and highly contagious
disease affecting both domestic and wild small ruminants with high
mortality rates (Banyard et al., 2010). PPR is responsible for great
economical losses in endemic regions of Africa, Middle and Near-East
and Asia (Kaukarbayevich, 2009; Munir et al., 2013). The disease
reached Europe in June 2018 with an outbreak in Bulgaria. In recent
years, multiple outbreaks have been recorded in Turkey, Georgia and
the Maghreb region posing a threat to other countries in Europe. PPR
has been identified as the next target of a global eradication campaign
launched in 2015 by the World Organization for Animal Health (OIE)
and the Food and Agriculture Organization of the United Nations (FAO)
[38].
The disease´s causative agent is the Peste des Petits Ruminants virus
(PPRV), a negative-sense single-stranded RNA virus that belongs with
the Measles virus (MV), Canine Distemper Virus (CDV) and Rinderpest
virus (RPV) to the genus Morbillivirus in the Paramyxoviridae family
(Gibbs et al., 1979; ICTV, 2016). PPRV genome is approximately 16 kb
in length and encodes six essential structural proteins: nucleoprotein
(N), phosphoprotein (P), matrix (M) protein, fusion (F) protein, he-
magglutinin (H) protein, large RNA-dependent polymerase (L) protein,
and two non-structural proteins (C and V), arranged in the following
order: 3’-N-P/C/V-M-F-H-L-5’ (Bailey et al., 2005).
Currently, the signaling lymphocyte activation molecule (SLAM,
also called CD150) is recognized as the main PPRV receptor, interacting
with the H protein of the virus (Sato et al., 2012). However, before the
SLAM was recognized, the CD46 molecule had been widely studied as
the main receptor, mainly because of its presence in Vero cells, an
African green monkey derived cell line commonly used for PPRV
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isolation (Hamdy et al., 1976; Lefèvre and Diallo, 1990). Nectin-4 has
also been described as an alternative receptor used by PPRV (Birch
et al., 2013; Fakri et al., 2016). In addition, the tyrosine kinase receptor
(ALK) was included as a receptor candidate to PPRV infection in vitro
(Chaudhary et al., 2015).
For successful in vitro replication of PPRV, most of the studies focus
on the use of the Vero cells (Balamurugan et al., 2010; Diallo et al.,
1989; Kumar et al., 2016). In addition to these, the marmoset B95a cells
(Sen et al., 2014) have also been used to isolate PPRV. The isolation of
wild-type PPRV in non-ruminant cells can take several blind passages
before the observation of a cytopathic effect (Saliki et al., 1994). The
time needed for PPRV isolation has been shortened through the use of
modified cell lines, mainly Vero cells expressing morbillivirus re-
ceptors. VeroDogSLAM or also CHS-20, a monkey CV1 cell, are mod-
ified cell lines that express dog or goat SLAM, respectively (Adombi
et al., 2011; Sato et al., 2012; Seki et al., 2003). In addition to these,
VeroNectin-4, a Nectin-4 expressing cell line, has been used successfully
for PPRV isolation (Fakri et al., 2016).
Besides the queries on the main receptor for PPRV entry, both in
vitro and in vivo, many gaps persist in the elucidation of the effects of
the innate immune response on PPRV replication. PPRV replication was
shown to be reduced in Vero cells pre-treated with human type I in-
terferon alpha (IFNα) (Dhanasekaran et al., 2014). However, PPRV can
inhibit the type I interferon (type I IFN) pathway through the expres-
sion of the V and C protein (Ma et al., 2015; Sanz Bernardo et al., 2017),
and more recently described, also through the expression of N protein
(Zhu et al., 2019).
Notwithstanding the remaining questions about PPRV pathogenesis
and permissiveness in vitro, there is a lack of a small animal model for
PPRV in vivo studies. This condition has delayed the progress in the
understanding of virus-host interactions and the validation of new
vaccines and therapeutic tools against PPR.
Aiming to mimic the appropriated conditions for the development
of a future mice model to PPRV infections, we first looked for mouse
cell lines, in which we introduced the goat SLAM receptor to promote
PPRV infection. Unexpectedly, this approach ended up with the iden-
tification of a mouse fibroblastic embryonic cell line C3H/10T1/2
(10T1/2) with selective permissiveness to different PPRV strains, in the
presence or absence of the goat SLAM receptor.
Our results indicate that the attenuated PPRV strains analyzed here
display a defective replication in 10T1/2 cells, while virulent strains
successfully completed their life cycle, resulting in a productive infec-
tion. These results seem to be independent of goat SLAM receptor ex-
pression and the innate antiviral type I IFN response of the cells.
Interestingly, a vaccine measles virus strain (MV) showed the same
behavior than the vaccine PPRV. Since PPRV attenuated vaccine strains
can enter the cells but cannot replicate in the 10T1/2 cell line, we
propose these cells as an alternative tool for PPRV-host interaction and
virulence studies. In addition, further analyses are needed to evaluate
the interest of these cells for other morbilliviruses.
2. Materials and Methods
2.1. Cells and viruses
ETM52 cells, an ovine embryonic cells, obtained from Dr. Pierre
RUSSO, ANSES Sophia Antipolis (Thabti et al., 2002), and Vero cells, an
African green monkey kidney cells, (ATCC CCL-81, USA) were cultured
in Minimum Essential Medium (MEM). C3H/10T1/2 (10T1/2) cells, a
mouse fibroblastic embryonic cell, (ATCC CCL-226, USA) were cultured
in Basal Medium Eagle (BME). All mediums were supplemented with
2mM L-Glutamine and 10% fetal bovine serum. All mediums and re-
agents are from Gibco Life Technologies, USA. Cells were cultured at
37 °C and 5% CO2.
The PPRV Nigeria 75/1 wild and vaccine strains (accession no.
X74443), and India 94/1 virulent strain were obtained from a collection
available in our laboratory, while the vaccine strain Sungri 96 (acces-
sion no. KF727981) was obtained from MSD Animal Health (The
Netherlands). The two first strains belong to the lineage II while the two
others are clustered into lineage IV (Kerur et al., 2008). The vaccine
strain Schwarz measles vaccine (MV-Schwarz) was obtained from Dr
Frédéric Tangy, Pasteur Institute (France).
Viral stocks were prepared by collecting infected Vero cells with the
supernatants when approximately 80% of the cells displayed cytopathic
effect (CPE). Cells were frozen/thawed three times before collection.
Finally, viral titers were determined using the Reed–Muench method
(Reed and Muench, 1938) and expressed as TCID50/mL. Virus stocks
were aliquoted and stored at - 80 °C.
2.2. Virus infection and cell assays
All cell assays were performed using 24h-seeded cells. All viral in-
fections were performed at multiplicity of infection (MOI) of 0.1. After
1 hour of virus adsorption, the inoculum was discarded and replaced
with an adequate volume of complete medium with 5% of fetal bovine
serum.
2.2.1. Kinetic study of PPRV strains in 10T1/2
10T1/2 and Vero cells were seeded in 96-wells plates (2×104 cells
per well). Vero cells were included as positive control to PPRV infec-
tion. Cells were infected with wild and vaccine Nigeria 75/1 strains,
India 94/1 and Sungri 96 strains. After 8 hours, 24 hours and 8 days
post-infection (pi), cells were fixated with acetone as described later
and subsequently analyzed for N-PPRV expression by immuno-
fluorescence assay (see paragraph 2.3.).
2.2.2. Viral entry assay
To evaluate the susceptibility of 10T1/2 cells to PPRV strains in-
fection, after 1 hour of virus adsorption, cells were washed with acid-
glycine buffer 0.6M at pH 2.5 (Sigma Aldrich, France) for 2 seconds
and again with PBS. Cells were then fixated and subsequently analyzed
for N-PPRV expression by immunofluorescence assay (see paragraph
2.3.).
2.2.3. Infection with other morbilliviruses and cell lines
10T1/2 cells were infected with MV-Schwarz. The presence of cy-
topathic effect (CPE) was analyzed during 8 days pi by microscopic
observation. The permissiveness of ETM52 cells to PPRV infection was
tested using the same conditions of infection and N-PPRV immuno-
fluorescence analysis. Cells were fixated and analyzed 72 hours pi.
2.2.4. Goat SLAM receptor, Poly I:C and RNA interference transfections
Transfections were performed using Lipofectamine 2000
(Invitrogen, USA) according to the manufacturer’s instructions. 10T1/2
and Vero cells were seeded in 24-wells plates (6×104 per well) and
were transfected using 0.6 μg of pCHS-GO1, an expression vector con-
taining goat SLAM coding sequence that was obtained from Dr. Adama
Diallo (FAO/AIEA, Vienna, Austria). At 24 hours post-transfection, cells
were infected with wild-type and vaccine Nigeria 75/1 strains.
The differences in cellular susceptibility to PPRV regarding the en-
dogenous type I IFN response were also determined. In 96-well plates,
10T1/2 cells were transfected with either the IFN inducer Poly I:C
(200 ng/ well, Sigma Aldrich, France) or a mouse siRNA targeting the
IFN-α/βRα (100 pmol/ well, Santa Cruz Biotech, USA), stimulating or
blocking the type I IFN response respectively. A mock-transfected
control was included in the experiment. At 24 hours post-transfection,
cells were infected with either wild-type or vaccine Nigeria 75/1
strains. Eight days after PPRV infection, virus replication was evaluated
by the presence of N-PPRV through immunofluorescence assay and the
expression of IFNα was obtained through a quantitative RT-PCR (RT-
qPCR) (see paragraph 2.3 and 2.4.3).
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2.3. Immunofluorescence assay
Cells were washed 3 times with PBS 1X and fixated with cold 80%
acetone for 30min at – 20 °C. They were washed twice with PBS and
permeabilized with 0.2% Triton X-100 (Sigma-Aldrich, France) for
10min at room temperature. After one wash with PBS 1X, cells were
blocked in 0.2% gelatin solution for 20min. Monolayers were im-
munostained with N-TRITC polyclonal antibody specific for PPRV nu-
cleoprotein produced in our laboratory, at a dilution of 1:100 for
30min at room temperature. Cells were washed twice with 0.2% ge-
latin solution and once with PBS 1× . Finally, cells were observed
under a fluorescence microscope (Olympus IX70, Japan).
2.4. RNA extraction and mRNA analyses by RT-PCR
All RNA extractions were performed using RNeasy Mini kit (Qiagen,
France) according to the manufacturer’s instructions. RNA samples
were qualified using a NanoDrop™ ND-1000 Spectrophotometer
(Thermo Fisher Scientific, USA) with an expected A260:A280 ratio
higher than 2. Genomic DNA (gDNA) contamination was removed with
TURBO DNA-freeTM Kit (Thermo Fisher Scientific, France) according to
the manufacturer’s instructions and the absence of gDNA amplification
was confirmed by control amplification without reverse transcription
reaction.
2.4.1. Expression of goat SLAM and nucleoprotein-PPRV genes by RT-qPCR
At 48 hours pi, total RNA was extracted from cells cultured in 24-
well plates. PolyA+mRNA was purified using the Oligotex mRNA Mini
Kit (Qiagen, UK).
Goat SLAM RT-qPCR assays were performed using Brilliant II SYBR®
Green QRT-PCR Master Mix Kit, 1-Step (Agilent, USA). Reactions were
performed in a final volume of 25 μL following the manufacturer’s
conditions with 2 μL of purified mRNA and 100 nM of final con-
centration of each primer (Table 1). Reactions were run on an
Mx3000 P instrument (Agilent, USA). The samples were tested in du-
plicate (from extraction to amplification) using the following RT-qPCR
1-step program: 50 °C for 30minutes; 95 °C for 10minutes; and 40 cy-
cles of 94 °C for 30 seconds, 56 °C for 1minute, and 72 °C for 30 sec-
onds. A final dissociation step was included in all reactions.
Nucleoprotein-PPRV (N-PPRV) RT-PCR assay was performed as
previously described (Kwiatek et al., 2010) (see Table 1).
2.4.2. Expression of matrix protein and hemagglutinin-PPRV genes by RT-
PCR
Using the same mRNA previously described, reverse transcription
was performed with SuperScript III First-Strand Synthesis SuperMix
(Invitrogen, USA), according to the manufacturer’s instructions. Then,
each sample was analyzed with conventional PCR. All reactions were
performed in a final volume of 25 μL containing: 2.5 μL of 10X PCR
buffer, 1 μL of dNTP 10μM, 1 U of Taq DNA polymerase, 2 μL of cDNA
and 400 nM of each primer (Table 1). The cycling program was as
follows: 94 °C for 5min; 35 cycles of 94 °C for 30 seconds, 55 °C for 30
seconds and 72 °C for 1minute; and a final step at 72 °C for 5minutes.
The PCR products attempted were 352 bp and 312 bp to matrix protein
and hemagglutinin PCR, respectively, and were analyzed by electro-
phoresis in 1.5% agarose gel.
2.4.3. Expression of IFNα in 10T1/2 cells by RT-qPCR
At 8 hours pi, total RNA was extracted from cells cultured in 24-well
plates. Aiming to access the quantification of IFNα expression, 84 na-
nograms of each RNA sample was reverse transcribed using the
SuperScript III First-Strand Synthesis SuperMix (Invitrogen, USA) ac-
cording to the manufacturer’s instructions.
Quantitative PCR reactions were performed using the Brilliant II
SYBR Green QPCR Master Mix (Agilent, USA) in a final volume of 25 μL
with 2 μL of cDNA and 600 nM of each primer (Table 1). The cycling
program was as follows: 95 °C for 10min; 40 cycles of 95 °C for 30
seconds, 60 °C for 1minute, and 72 °C for 30 seconds. All reactions were
performed in duplicate and included a final dissociation step.
Relative expression was normalized with β-actin gene and was
calculated with the comparative Ct method (ΔΔCt method) using the
following equation: 2 –ΔΔCt (Livak and Schmittgen, 2001). Differences in
gene expression were expressed as fold-changes (Log(2 –ΔΔCt).
2.4.4. Expression of CD46, Nectin-4, ALK and SLAM receptors by RT-PCR
Total RNA extracted from brains, lungs and blood of a NMRI (Naval
Medical Research Institute) mouse were used as positive control for
gene expression. RNA from the solid fresh tissues and blood was ex-
tracted with RNeasy mini Kit following the “Purification of Total RNA
from Animal Tissues” protocol including the DNase treatment step.
RNA was reverse transcribed using the SuperScript III First-Strand
Synthesis SuperMix (Invitrogen, USA) according to the manufacturer’s
instructions.
PCR assays for mouse ALK receptor were performed following the
Table 1
Primer sequences and references for PCR experiments.
Target gene Primer names Primer sequence (5’-3’) Tm (°C) Amplicon size (bp) Reference
Goat SLAM SLAM-BC0273F F- CAAAGGATCCCTTTCCTGGAG 56 249 (Adombi et al., 2011)
SLAM-BC0273R R- CATGGACTCGATTCTGAGGAG
Nucleoprotein NPPRf F- GAGTCTAGTCAAAACCCTCGTGAG 55 351 (Kwiatek et al., 2010)
NPPRr R- TCTCCCTCCTCCTGGTCCTC
Matrix protein MP54 F- AGGAGCAAGGGCAAC 55 352 Diallo and Minet, 1994 (unpublished)
MP47 R- AGTCCTGCCGTGCGCCTCACC
Hemagglutinin protein HP46 F- CGCACAAAGGGAAAGGATCA 55 312 Diallo and Minet,1994 (unpublished)
HP47 R- CTGATGCCGACTTCATCACC
IFNα IFNαf F- CTGCTGGCTGTGAGGACATA 60 115 (Wang et al., 2013)
IFNαr R- AGGAAGAGAGGGCTCTCCAG
β-actin βact1 F- ACCAACTGGGACGACATGGAGA 55 455 (Minet et al., 2009)
βact2 R- AGCTGGTCCTGCTCGAAGTC
ALK Mouse ALKF F- TTCTCCTTGTGAGCTCCGCA 58 296 (Lu et al., 2015)
Mouse ALKR R- TCCACTGATGGTAAGGTAGC
CD46 CD46F F- ATGCCTGTGAACTACCACGG 60 275 In house
CD46R R- TTTAGCTCGAGCACCCCATG
Mouse SLAM Mouse SLAMF F- CAAAGGATCCCTTTCCTGGAG 55 720 In house
Mouse SLAMR R- CATGGACTCGATTCTGAGGAG
Nectin-4 Nectin4 CDSF F- GGATTCTCAGGTCACTGTGG 61 399 mouse
477 monkey
In house
Nectin4 CDSF R- TTCATGGCCTGTTTGATGCC
1Abbreviations: F, forward; R, reverse; bp, base pairs; Tm, melting temperature.
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protocol described by Lu et al. (2015) (Lu et al., 2015). PCR assays for
mouse CD46, SLAM receptor and mouse and monkey nectin-4 were
developed in this study. Primers were designed with Primer3 Software
2.4.0 (Untergasser et al., 2012) on the following sequences mouse CD46
(accession number NM_010778.4), mouse SLAM receptor
(NM_013730.4), mouse nectin-4 receptor (NM_001122680) and
monkey nectin-4 receptor (XM_001117709). All reactions were per-
formed in a final volume of 25 μL containing: 2.5 μL of 10X PCR buffer,
1 μL of dNTP 10μM, 1 U of Taq DNA polymerase, 2 μL of cDNA, 400 nM
of each primer. The cycling conditions were as follows: 94 °C for 5min;
35 cycles of amplification at 94 °C for 45 seconds, primer-specific an-
nealing temperature for 45 seconds and 72 °C for 1minute; and a final
extension of 72 °C for 5minutes. The PCR products were analyzed by
electrophoresis in 1.5% agarose gel. Amplicons from control samples
and 10T1/2 cells were sequenced by Beckman Coulter Genomics (Ta-
keley, United Kingdom) through Sanger methodology and their nu-
cleotide sequence analyzed using the software Geneious version 6.1
(http://www.geneious.com) (Kearse et al., 2012). The primer se-
quences, annealing temperatures and amplicon sizes are listed in
Table 1.
3. Results
3.1. PPRV strains show different replication level in 10T1/2 cell line
The 10T1/2 permissiveness to PPRV virulent and attenuated strains
was evaluated by an immunofluorescence assay against the viral nu-
cleoprotein (N-PPRV) at different time points post-infection. A steady
and rapid increase in virus production was observed over time in the
cells inoculated with the two virulent strains, wild-type Nigeria 75/1
and India 94/1. In contrast, cells infected with the attenuated strains,
vaccine Nigeria 75/1 and Sungri 96 of the corresponding lineages II and
IV, respectively, showed a stable low level of N-PPRV expression at all
time points (Fig. 1A).
Since the entry of virulent PPRV strains in the mouse 10T1/2 cells
was unexpectedly easy, we further looked at the expression of PPRV cell
receptors. RT-PCRs were performed to assess expression of SLAM,
CD46, ALK-tyrosine kinase and Nectin-4 mouse receptors. CD46 and
ALK but not Nectin-4 or SLAM receptors are expressed in 10T1/2 cells
(Figure S1,2). However, the same profile is found in Vero cells, into
which virulent and attenuated PPRV strains replicate efficiently (Figure
S2) (Chaudhary et al., 2015; Lecouturier et al., 1996; Noyce et al.,
2011). We further checked whether trans-expression of the goat SLAM
PPRV-receptor in 10T1/2 could improve the replication of attenuated
PPRV strains. 10T1/2 cells were transfected with a plasmid expressing
the goat SLAM receptor. The expression of goat SLAM receptor was
confirmed 24 hours post-transfection by a RT-qPCR targeting its mes-
senger RNA (mRNA); however, no modification in the cell permissive-
ness to PPRV was observed (Table S1).
To identify the stage of the virus replication cycle where PPRV
vaccines are blocked in 10T1/2 cells, we first examined the ability of
these strains to enter in these cells (classically defined as susceptibility).
Infected cells were washed with PBS 1X and then with an acidic buffer
solution to remove any bound, but non-internalized virus. Both wild-
type and attenuated PPRV strains were able to enter 10T1/2 cells, as
shown by the immunofluorescence results (Fig. 1A).
Additionally, conventional RT-PCR was performed to detect mRNA
of H and M proteins at 24 hours post infection (pi). The results showed
an equal expression of PPRV transcripts in attenuated and virulent
Nigeria 75/1 PPRV strains at early stages of the infection, suggesting
that the blockage of the attenuated strain occurs later in the virus re-
plication cycle (Figure S3).
As an additional control for virus infection, all PPRV strains were
inoculated in Vero cells and immunofluorescence for N-PPRV detection
was performed at 1 hour and 8 days pi in this cell line. The replication
cycle of PPRV strains occurred as expected (Fig. 1B, C).
3.2. Replication-defective of attenuated PPRV is not reproduced in ETM52
cells
In order to assure that the differences observed on the interaction
between the PPRV strains and 10T1/2 cell line are specific events
linked to the mouse cell, a cell line from a PPRV host species was in-
cluded in the tests. ETM52, a sheep embryonic cell line, were in-
oculated with both PPRV attenuated strains and the wild-type India 94/
1 strain and, 72 hours pi, the N-PPRV expression was analyzed by im-
munofluorescence. The ETM52 cells were found equally susceptible to
attenuated and virulent PPRV strains, as demonstrated by the high
number of N-PPRV positive cells 72 hours pi (Fig. 1D).
3.3. Type I IFN response does not interfere with the PPRV replication cycle
Type I IFNs are known to inhibit morbillivirus replication and,
conversely, wild-type morbilliviruses may down-regulate the IFN re-
sponse through the expression of C, V and W proteins (Avia et al., 2016;
Ma et al., 2015; Sanz Bernardo et al., 2017; Sparrer et al., 2012). On the
other hand, some vaccine strains seem to lose their capacity to down-
regulate the IFN response while still being controlled by type I IFNs.
This lost property would result from mutations in the non-structural
genes (Chinnakannan et al., 2013; Sparrer et al., 2012). Accordingly,
we investigated whether type I IFN responses could be responsible for
the control of vaccine strains replication in 10T1/2 cells. Untreated and
type I IFN-induced or -suppressed cells were infected with vaccine and
wild-type PPRV strains.
A RT-qPCR to IFNαmRNA was applied to estimate IFN expression in
these experiments 8 hours after PPRV infection (Fig. 2). Expression of
IFNα mRNA was not detected in any other conditions than those in-
volving cells transfected with Poly I:C. Infection by vaccine and wild-
type PPRV strains do not induce IFNα response. In contrast, both at-
tenuated and virulent PPRV strains inhibit the IFN response induced by
Poly I:C, the virulent strain being more active, with 78% of reduction,
compared to 39% with the attenuated strain, probably because the
former does a complete replication cycle whereas the latter does not. A
short interfering RNA (siRNA) against to IFN-α/βRα was introduced in
10T1/2 cells to block type I IFN expression in response to PPRV in-
fection. However, as no PPRV strain was able to induce mRNA IFNα in
this cell line, the siRNA action could not be observed.
PPRV replication was determined by the detection of N-PPRV ex-
pression by the immunofluorescence assay at 8 days pi. Whatever the
cell treatment, no differences in the virus replication were seen (Fig. 3).
The vaccine strains were never able to replicate in 10T1/2 cells, at least
for the first 8 days pi, in presence or absence of IFNα. In contrast, the
wild type strains showed efficient replication under all cell treatments,
including cells pretreated with Poly I:C (Fig. 2).
3.4. Attenuated MV exhibit the same behavior of PPRV vaccine strains in
10T1/2 cells
A vaccine strain of measles virus (MV-Schwarz) was tested in par-
allel with PPRV on 10T1/2 cells. 10T1/2 cells infected with MV-
Schwarz were observed for 8 days pi and presence of CPE was never
detected (data not shown).
4. Discussion
Peste des Petits Ruminants is the cause of huge socio-economic
problems in endemic countries. Following the rinderpest example, a
global PPR control and eradication strategy started in 2015, aiming at
the eradication of PPR by 2030 (FAO, 2015). All experts’ efforts are
now focused in bridging gaps on the actual knowledge on PPRV pa-
thogenesis and control, to achieve the aim of this global campaign. In
order to understand the virus-host interactions that determine patho-
genesis, it is desirable to generate a small animal model for the disease
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Fig. 1. Expression of N-PPRV in 10T1/2, Vero and ETM52 cell lines. (A) Immunofluorescence to N-PPRV showing the infection kinetics of the different PPRV strains
at four time points pi in 10T1/2 cells (B) and in two time points pi in Vero cells. At 8 days pi, the India 94/1 strain completely destroyed the Vero cell monolayer
(figure not included). (C)Mock-infected 10T1/2 and Vero cells were used as negative controls (D) and the ovine embryonic cell line ETM52 was used as an additional
embryonic cell control. Image magnification 10× .
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or an in vitro biological system. With the objective to develop a future
transgenic mouse model to study PPRV pathogenesis, we first started to
study the permissiveness of a mouse embryonic 10T1/2 cell line to
PPRV infection in order to determine whether the constitutive expres-
sion of a caprine receptor in these cells and later on in mice, would be a
prerequisite to allow PPRV entry.
In a first experiment including wild-type Nigeria 75/1 and India 94/
1 PPRV strains, which are usually more difficult to propagate in cell
culture (Vero, B95a cells) compared to attenuated strains, an intense
replication in 10T1/2 cells was observed at the outset, leading to the
development of extensive CPE throughout the monolayers. Even if these
cells express the murine CD46 and ALK receptors, we were not ex-
pecting an efficient interaction of these murine receptors with wild-type
PPRV strains. Indeed, optimal in vitro adaptation of wild-type morbil-
liviruses usually requires several passages in cell culture, often resulting
in attenuation of the strains for the host species (Ishii et al., 1986; Lee
et al., 2016). This is how the attenuation of the Nigeria 75/1 vaccine
strain was achieved in Vero cells, which is a monkey cell line (Diallo
et al., 1989). Another surprising finding was that the replication of the
attenuated Nigeria 75/1 and Sungri 96 PPRV strains was not observed
in 10T1/2 cells. Even in the presence of a goat SLAM receptor in these
cells, the attenuated PPRV strains were not able to replicate, suggesting
that the inhibition was not resulting from the absence of a PPRV re-
ceptor. Furthermore, after removal of non-internalized viruses shortly
after adsorption, entry of the vaccine strains was confirmed by im-
munofluorescence. These results agree with a previous study, which
showed that 2minutes after adsorption, the nucleocapsids from para-
myxovirus can be already found in the cell cytoplasm (Singh and
Helenius, 1992). In 10T1/2 cells, both wild-type and vaccine strains
expressed intracytoplasmic mRNA of N, M and H PPRV proteins,
showing that vaccine strains can enter the cells and start transcription.
It suggests that the blockage occurs later in the virus replication cycle.
These observations highlight important differences in virus-host inter-
action between attenuated and wild PPRV strains.
Mechanisms used by the host to control the morbillivirus life cycle,
or even by the virus to escape from the host immune defenses, are in
constant study and many questions remain unsolved. Chinnakannan
Fig. 2. Relative expression of IFNα mRNA in different conditions of infection
with of 10T1/2 with the vaccine or wild-type Nigeria 75/1 strains.
Upregulation of IFNα mRNA was observed whenever the cells were transfected
with Poly I:C. Nigeria 75/1 wt and vac strains downregulated IFNα mRNA
expression 8 hours pi. CC: cell control (not treated or infected); wt: wild type;
vac: vaccine.
Fig. 3. Nigeria 75/1 wild-type and vaccine strains replication in untreated, type I IFN activated (transfected with Poly I:C) or type I IFN suppressed (transfected with
siRNA against IFNAR) 10T1/2 cells. The immunofluorescence to N-PPRV was performed 8 days pi. Image magnification 10× .
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et al., for example, have found different abilities of the morbillivirus
species to block IFN from a same cell line (Chinnakannan et al., 2013).
Dhanasekaran et al focused on the observation of innate antiviral im-
mune responses caused by the same PPRV strain in different species of
goats and buffaloes and found that high type I IFN levels in buffaloes
may afford reduced virus replication (Dhanasekaran et al., 2014). Other
studies have shown differences in IFN susceptibility and IFN blocking
ability of morbilliviruses, such as the canine morbillivirus (CDV) being
susceptible to IFN response (Carvalho et al., 2014), while PPRV actively
blocking the induction of IFN (Chinnakannan et al., 2014; Zhu et al.,
2019).
Referring to the studies previously quoted, we investigated the role
of type I IFN response. Our hypothesis was that attenuated strains might
be more susceptible to the IFN response of 10T1/2 cells or less likely to
control this response compared to virulent strains. However, the results
indicated that both wild and attenuated Nigeria 75/1 PPRV could
down-regulate the synthesis of type I IFN mRNA, the wild-type strain
reducing about 3 times more the synthesis of IFNα transcripts compared
to the vaccine strain. These findings reinforce the results observed by
others, which confirmed the interference of morbilliviruses with the
type I IFN signaling pathways (Ma et al., 2015; Sanz Bernardo et al.,
2017; Stewart et al., 2014). In addition, IFNα expression level in 10T1/
2 cells is not affected by the infection with either a wild or vaccine
PPRV strains and vaccine PPRV strains replication is not increased
when IFNα expression is inhibited. These results suggest that the spe-
cific behavior of those vaccine strains in 10T1/2 cells is due to another
mechanism.
All together, our results indicate that neither absence of specific
morbillivirus cellular receptor or type I IFN are responsible for the in-
hibition of attenuated virus in 10T1/2 cells. Transcriptomic profile of
cells infected with attenuated and virulent PPRV will be a useful tool in
order to raise alternative hypotheses on the origin of the different re-
plication capacity displayed by these virus strains. Alternatively, dif-
ferences in the genome sequence between wild-type and attenuated
virus could provide important information about viral proteins that are
determining virus attenuation and, thus, a possible key player involved
in the viral-host interaction (Billing et al., 2014; Chen et al., 2015). An
analysis of these mutations between vaccine and wild-type PPRV Ni-
geria 75/1 strains was carried out by our group and we were able to
identify putative mutations associated with virus attenuation (Eloiflin
et al., 2019). We intend now to deep our study and verify if these
mutations are involved in the attenuated versus virulent behavior of
PPRV in 10T1/2 cells.
This study demonstrated for the first time differences in the inter-
action between vaccine and wild-type PPRV strains in 10T1/2 cells.
Furthermore, this peculiarity for PPRV could be shared by other mor-
billiviruses as shown here for attenuated measles virus. This cell line is
a useful tool to study viral and cellular factors involved in virulence of
morbilliviruses.
Accession numbers
Nigeria 75/1 vaccine strain: X74443; Sungri 96 vaccine strain:
KF727981 (Siddappa et al., 2014), wild-type PPRV Nigeria 75/1 strain:
Genbank submission in progress.
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